Experimental compound promoted for cognition from animal memory rescue and laboratory nerve-connection work. Human benefit and long-term safety unproven; core mechanism papers retracted. Concerns include unknown human safety, product-quality variability, and theoretical cancer risk from growth-pathway activation. Related clinical drug did not clearly improve thinking in Alzheimer trials. Evidence for human cognitive enhancement is low to speculative. (Full Review)

Protocol

Dose

~5–20 mg oral once daily

Community range; unvalidated; no approved human dose

Cycling

4–8 weeks on / 2–4 weeks off

Common clinic pattern; caution rather than efficacy data

Routes

Oral; topical / intranasal also used

Comparative human bioavailability unknown

Time to effect

Animal memory rescue

Within days

Around learning tasks in deficit models

Human anecdotal onset

1–4 weeks

Uncontrolled clinic and community reports

Benefits

Low: Spatial memory rescue in cognitive-deficit animal models; synaptogenesis and spinogenesis; neuroinflammation reduction in Alzheimer’s disease–model mice

Speculative: Cognitive enhancement in healthy or mildly impaired humans; disease-modifying benefit in Alzheimer’s or Parkinson’s disease via Dihexa itself

Contraindications

Active cancer or recent malignancy (especially c-Met–driven tumors)

Undiagnosed suspicious masses pending workup

Pregnancy and breastfeeding

Children and adolescents

Seeking FDA-approved, evidence-based dementia therapy (Dihexa is not one)

Key Interactions

Growth-pathway oncology drugs (c-Met / HGF inhibitors such as capmatinib, tepotinib)

Proliferative biologic therapies and some growth-factor agents

Other experimental nootropic peptides (e.g., cerebrolysin, PE-22-28, high-dose growth hormone secretagogues)

Strong CYP modulators (e.g., ketoconazole, rifampin, grapefruit juice)

Anticholinergic cognitive burden (diphenhydramine, some bladder antispasmodics)

Supplements with pro-angiogenic or high-dose growth claims

Risk & Side Effects

Medium: Uncharacterized human safety of Dihexa itself

Low: Acute tolerability symptoms; research-chemical quality and contamination risk

Speculative: Tumor promotion via sustained HGF/c-Met activation; unknown developmental, cardiac, or off-target growth effects

Monitoring

Marker	Target	Why
Cognitive composite (e.g., MoCA or digital battery)	Stable or improved vs personal baseline	Tracks the intended endpoint
hs-CRP	Generally <1.0 mg/L	Flags inflammatory confounders of cognition
TSH, free T4	TSH roughly 0.5–2.5 mIU/L	Thyroid dysfunction mimics cognitive decline
Vitamin B12 / methylmalonic acid	B12 often >400–500 pg/mL with normal MMA	Deficiency causes reversible cognitive symptoms
Fasting glucose / HbA1c	Glucose ~70–90 mg/dL; HbA1c often <5.5%	Metabolic health modulates brain aging
Age-appropriate cancer screening	Per guidelines	Partially addresses theoretical c-Met risk
CBC / CMP	Within lab reference	Basic organ safety net

Cadence: Baseline; 2–4 weeks; end of each cycle; prompt evaluation for red-flag symptoms

Qualitative Assessment

Working memory and recall in daily tasks
Attention stamina and mental fatigue
Mood stability and anxiety
Sleep quality and dream intensity
Headache, irritability, or GI change after dose changes

Dihexa for Cognitive Enhancement

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment